Literature DB >> 6166677

Fluid-phase SC5b-8 complex of human complement: generation and isolation from serum.

S Bhakdi, M Roth.   

Abstract

A rapid, simple method for isolating SC5b-9 generated in human serum, and SC5b-8 generated in C9-depleted serum is described. The procedure leads to approximately 30% recovery of either complex and consists of polyethyleneglycol precipitation followed by 1 DEAE ion exchange chromatography and a sucrose density gradient ultracentrifugation. The SC5b-8 complex is a water-soluble macromolecular of alpha-electrophoretic mobility. Apart from the absence of C9, it exhibits an identical SDS-gel electrophoresis polypeptide pattern as SC5b-9. A sedimentation coefficient of 19 to 20S and an effective molecular radius of approximately 10 nm were determined by sucrose density gradient centrifugation and gel filtration, respectively. From these values, a m.w. of 800 to 850,000 is tentatively assigned to the SC5b-8 complex. The S-protein was not dissociable from either SC5b-8 or SC5b-9 through treatment with desoxycholate and no alterations in the hydrodynamic properties of either complex were discernible after action of this detergent.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6166677

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  13 in total

1.  Complement S-protein (vitronectin) is associated with cytolytic membrane-bound C5b-9 complexes.

Authors:  S Bhakdi; R Käflein; T S Halstensen; F Hugo; K T Preissner; T E Mollnes
Journal:  Clin Exp Immunol       Date:  1988-12       Impact factor: 4.330

2.  The cytolytic C5b-9 complement complex: feedback inhibition of complement activation.

Authors:  S Bhakdi; F Maillet; M Muhly; M D Kazatchkine
Journal:  Proc Natl Acad Sci U S A       Date:  1988-03       Impact factor: 11.205

Review 3.  The membrane attack complex.

Authors:  H J Müller-Eberhard
Journal:  Springer Semin Immunopathol       Date:  1984

4.  Quantitative evaluation of the terminal C5b-9 complement complex by ELISA in human atherosclerotic arteries.

Authors:  F Niculescu; F Hugo; H G Rus; R Vlaicu; S Bhakdi
Journal:  Clin Exp Immunol       Date:  1987-08       Impact factor: 4.330

5.  Persistent complement activation on tumor cells in breast cancer.

Authors:  F Niculescu; H G Rus; M Retegan; R Vlaicu
Journal:  Am J Pathol       Date:  1992-05       Impact factor: 4.307

6.  In vivo clearance studies of the terminal fluid-phase complement complex in rabbits.

Authors:  F Hugo; C Berstecher; S Krämer; W Fassbender; S Bhakdi
Journal:  Clin Exp Immunol       Date:  1989-07       Impact factor: 4.330

7.  SP-40,40, a newly identified normal human serum protein found in the SC5b-9 complex of complement and in the immune deposits in glomerulonephritis.

Authors:  B F Murphy; L Kirszbaum; I D Walker; A J d'Apice
Journal:  J Clin Invest       Date:  1988-06       Impact factor: 14.808

8.  Measurement of terminal complement complexes in rheumatoid arthritis.

Authors:  B P Morgan; R H Daniels; B D Williams
Journal:  Clin Exp Immunol       Date:  1988-09       Impact factor: 4.330

9.  Quantitative measurement of SC5b-9 and C5b-9(m) in infarcted areas of human myocardium.

Authors:  F Hugo; T Hamdoch; D Mathey; H Schäfer; S Bhakdi
Journal:  Clin Exp Immunol       Date:  1990-07       Impact factor: 4.330

10.  Molecular cloning of S-protein, a link between complement, coagulation and cell-substrate adhesion.

Authors:  D Jenne; K K Stanley
Journal:  EMBO J       Date:  1985-12-01       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.